Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Biogen Community
NasdaqGS:BIIB Community
3
Narratives
written by author
0
Comments
on narratives written by author
86
Fair Values set
on narratives written by author
Community Investing Ideas
Biogen
Popular
Undervalued
Overvalued
Biogen
AN
AnalystConsensusTarget
Consensus Narrative from 29 Analysts
Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth
Key Takeaways Biogen is positioned for long-term growth through expanding global access to key therapies, leveraging increasing disease diagnoses and improved healthcare infrastructure. Streamlined operations, diverse late-stage pipeline, and digital engagement efforts are expected to strengthen earnings and reduce future revenue volatility.
View narrative
US$168.08
FV
19.7% undervalued
intrinsic discount
-2.05%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
51
users have followed this narrative
1 day ago
author updated this narrative
Biogen
AN
AnalystLowTarget
Consensus Narrative from 29 Analysts
Rising Drug Pricing Pressures And Generic Competition Will Depress Prospects
Key Takeaways Heightened pricing pressures, stricter reimbursement, and payer resistance threaten both revenue growth and the profitability of existing and new therapies. Intensifying competition, shifting innovation trends, and pipeline challenges risk eroding market share, margins, and long-term financial stability.
View narrative
US$115.00
FV
17.3% overvalued
intrinsic discount
-4.94%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
6 days ago
author updated this narrative
Biogen
AN
AnalystHighTarget
Consensus Narrative from 29 Analysts
Aging Demographics And Genetic Advances Will Unlock Neurological Breakthroughs
Key Takeaways Accelerated adoption of new Alzheimer's and rare disease therapies, aided by diagnostics, advocacy, and expanding guidelines, is poised to drive outsized revenue growth and operating leverage. Strategic partnerships, pipeline innovation, and demographic trends support sustained demand, pipeline expansion, and long-term margin improvement in neurology and rare disease markets.
View narrative
US$249.66
FV
46.0% undervalued
intrinsic discount
0.56%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
9 days ago
author updated this narrative
Your Valuation for
BIIB
BIIB
Biogen
Your Fair Value
US$
Current Price
US$134.94
54.1% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
14b
2015
2018
2021
2024
2025
2027
2030
Revenue US$9.5b
Earnings US$1.5b
Advanced
Set Fair Value